Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis.

BJUI compass·2026

Same author

Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.

Clinical genitourinary cancer·2026

Same author

<i>BRCA2</i> and <i>NF2</i>-Mutated High-Grade Renal Cell Carcinoma: A Case Report and Literature Review.

International journal of surgical pathology·2026

Same author

Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.

Nature medicine·2026

Same author

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

CA: a cancer journal for clinicians·2025

Same author

Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology.

Journal for immunotherapy of cancer·2025

Search research articles

Related Experiment Video

Updated: Feb 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Promising immunotherapy for prostate cancer.

John C Henegan¹, Guru Sonpavde²

¹a Division of Hematology and Oncology, Department of Medicine , University of Mississippi Cancer Center , Jackson , MS , USA.

Expert Opinion on Biological Therapy

|December 13, 2017

Summary

New immunotherapies, including personalized peptide vaccines, show promise for prostate cancer management. Combinations of agents are demonstrating encouraging activity, though further research is needed to optimize patient and agent selection.

Keywords:

Antigen spreading DNA vaccines autologous vaccines chimeric antigenreceptor-modified ‘designer’ T cells gene-mediated cytotoxic immunotherapy immunotherapy personalized peptide vaccines prostate cancer sipuleucel-T viral-based vaccines

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Experiment Videos

Last Updated: Feb 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Area of Science:

Oncology
Immunology
Urology

Background:

Sipuleucel-T is the sole approved immunotherapy for prostate cancer.
Emerging immunotherapies are being investigated for prostate cancer treatment, alone or in combination.

Purpose of the Study:

To review clinical trials of novel immunotherapies for prostate cancer.
To discuss the potential of vaccines, monoclonal antibodies, immune modulators, and cellular therapies.

Main Methods:

Review of clinical trials involving various immunotherapy agents.
Analysis of efficacy data, including overall survival and progression-free survival.

Main Results:

Personalized peptide vaccines show potential for improving overall survival in early trials.
Monoclonal antibody trials as single agents have not shown significant survival benefits.
Combination immunotherapies demonstrate encouraging activity in prostate cancer management.

Conclusions:

Further development requires rational models of immune system interaction with prostate cancer.
Reconsideration of traditional efficacy surrogates like progression-free survival may be necessary.
Optimizing agent and patient selection is crucial for advancing prostate cancer immunotherapy.